Federal News

Displaying results 1-10 (of 75)
 |<  < 1 2 3 4 5 6 7 8  >  >| 

CSRO’s Dr. Robert Levin Discusses Drug Pricing in the U.S.

CSRO Board Member, Robert Levin, participated in the Healthcare Policy podcast on February 18 to discuss federal prescription drug pricing reform. In his capacity as a practicing physician, and president the Alliance for Transparent and Affordable Prescriptions, Dr. Levin provided expert testimony on drug pricing reform proposals and how the drug supply chain works.

READ MORE

PBMs and New Approaches to Drug Pricing in 2019

Without a doubt, lowering list-prices for prescription drugs was a national focus in 2018. Coupled with numerous advocacy organizations bringing increased awareness to Pharmacy Benefit Managers’ (PBMs) unfair practices, and their effect on drug prices, several reforms have sparked across the U.S. and are expected to increase in intensity in 2019.

READ MORE

CSRO Submits IPI Comments

Prior to commenting on the proposed International Pricing Index Model (IPI) for Part B drugs, CSRO leadership met with Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma to convey rheumatology's perspective.

READ MORE

Express Scripts Announces New Formulary Design Option

This week, Express Scripts announced that it would provide clients with the ability to opt for its new National Preferred Flex Formulary Design. As opposed to favoring drugs that garner the most rebate dollars, the new benefit design intends to favor drugs that have lower list prices to begin with.

READ MORE

CSRO Discusses New Drug Payment Model with Key Agency Officials

Last week, CSRO’s Past President and National Advocacy Chair, Michael Schweitz, MD, participated in one-on-one discussions with Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma and Special Advisor to the Administrator Jeet Guram, MD, to discuss details about the Trump Administration’s potential International Pricing Index Model for Medicare Part B Drugs.

READ MORE

CSRO Discusses Part B and D with CMS

Members of CSRO’s executive board recently met with CMS to discuss Part B and D drug pricing. Doctors Michael Schweitz, Madelaine Feldman, Greg Schimizzi traveled to D.C. to present CSRO’s feedback on recent proposals and provide rheumatology’s perspective on the programs.

READ MORE

CSRO Responds to RFI Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs

CSRO has submitted their comments regarding the Request for Information (RFI) by the Department of Health and Human Services.

READ MORE

CSRO Presents on PBMs at the Board of Hispanic Caucus Chairs Conference

CSRO Vice President, Dr. Madelaine Feldman recently presented on Pharmacy Benefit Managers and utilization management tools at the Board of Hispanic Caucus Chairs meeting in Las Vegas, Nevada.

READ MORE

FDA Biosimilars Educational Material

To date, the U.S. Food and Drug Administration (FDA) has approved seven biosimilars, and some are already on the market. As the biosimilars market continues to grow, there are still a lot of questions from both patients and physicians about these important new treatment options.

READ MORE

CSRO Opposes Efforts to Establish a National Benchmark Plan Standard for Prescription Drugs

The CSRO has submitted comments to CMS expressing concerns with their intent to establish a national benchmark plan standard for prescription drugs in future years.

READ MORE

Displaying results 1-10 (of 75)
 |<  < 1 2 3 4 5 6 7 8  >  >|